Rapport Therapeutics (RAPP) Corporate presentation summary

Leadership and expertise

• Management and board include industry veterans with extensive neuroscience, biotech, and pharma experience.

• Leadership has backgrounds from major companies such as Janssen, Lilly, Biogen, Genentech, and Alnylam.

Precision neuroscience platform and pipeline

• Focus on small molecule precision medicines for neurological and psychiatric disorders.

• Lead program RAP-219 targets TARPγ8, a receptor associated protein, with potential first-in-class status.

• Pipeline includes programs for epilepsy, bipolar mania, chronic pain, migraine, and hearing/vestibular disorders.

• RAP-219 is being developed for multiple indications, including focal onset seizures (FOS), primary generalized tonic-clonic seizures (PGTCS), and bipolar mania.

Financial position and collaborations

• Cash and equivalents of $476.8 million as of March 31, 2026, with runway into 2H 2029.

• Collaboration with Tenacia for RAP-219 in Greater China includes $20 million upfront and up to $308 million in milestones plus royalties.